ClinicalTrials.gg
RecruitingNCT07079774Updated Sep 4, 2026

TrueLok Elevate PMCF Study

An observational study in Wound of Skin, Ulcers and Soft Tissue Defect, sponsored by Orthofix s.r.l.. Recruiting at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Orthofix s.r.l. · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
153
Ages
18 Years and older
Sex
All
01

Study summary

The TrueLok Elevate Transverse Bone Transport System is a modular external fixation device designed for transverse bone transport. It promotes local vascular and wound healing through controlled corticotomy and gradual distraction. The system is intended for adult patients with bony and/or soft tissuedefects.

02

Conditions studied

  • Wound of Skin
  • Ulcers
  • Soft Tissue Defect

Browse trials for

03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 62 are open to participants now.

This study's planned enrollment of 153 is above the median of 100 across 55 observational studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

Orthofix s.r.l. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients affected by chronic foot ulcers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aged 18 years or older at the time of surgery Willing and able to sign and date the study-specific form in accordance with national and institutional ethics requirements Willing and able to comply with requirements of the protocol, including follow-up requirements Indicated for surgical intervention using the TrueLok Elevate Transverse Bone Transport System for the treatment of soft tissue defects in the form of lower limb ulcers

Presence of a chronic ulcer, defined as:

  • Present for at least 3 months, and
  • Unresponsive to standard non-surgical or surgical wound management, including but not limited to debridement, negative pressure wound therapy (VAC), offloading, antibiotics, or vascular optimisation

Exclusion criteria

Exclusion Criteria:

Mental or cognitive impairment or physiological or behavioural conditions that, in the opinion of the investigator, would preclude reliable adherence to postoperative care instructions, follow-up assessments, or study procedures

Known or presenting with the following signs of a systemic inflammatory response syndrome (SIRS) as exhibiting two or more of the following conditions:

o

  • Heart rate >90 beats/min
  • Respiratory rate >20 breaths/min
  • PaCO2 \<32-mm Hg
  • White blood cell count >12.000 or \<4.000/cu mm
  • 10% immature (band) forms Known or allergy to any material used in the TrueLok Elevate Transverse Bone Transport System (e.g., stainless steel, titanium) Current participation in another interventional clinical study that, in the opinion of the investigator, may interfere with the objectives or outcomes of this study Presence of active or systemic infection that, in the investigator's opinion, may interfere with wound healing or the study protocol of less than 12 months Simultaneous bilateral application of the TrueLok Elevate Transverse Bone Transport System Current incarceration at the time of enrolment Any condition or clinical circumstance that, in the opinion of the investigator, would make participation not in the best interest of the subject or would interfere with the study objectives
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
153 participants (estimated)
Patient registry
No

Interventions

  • DeviceTransverse Bone Transport System

    This is a prospective, international, multicentre, observational post-market clinical follow-up (PMCF) study. Adult subjects will be treated according to the manufacturer's Instructions for Use, with follow-up extending to 12 months post-device removal. Participating sites include centres in the US, Europe, the UK, and South Africa. Subjects will be followed using a phased framework: T0: Index Surgery (baseline data, operative details, ulcer status) T1: End of Distraction (device parameters, adverse events, ulcer status) T2: End of Compression (similar to T1) T3: Device Removal (confirmation of union, ulcer status) Post-removal visits: F3: 3 months F6: 6 months F12: 12 months

06

What researchers measure

Primary outcomes

  1. Complete ulcer healing

    Proportion of subjects achieving complete ulcer healing within 12 months of device removal. Healing is defined as full epithelialisation with no open wound.

    Time frame: 12 months

07

Study locations

5 of 14 sites recruiting
  • Universitätsklinikum Halle
    Halle, 06120, Germany
    Not yet recruiting
  • Krankenhaus GmbH Landkreis Weilheim-Schongau
    Weilheim, 82362, Germany
    Not yet recruiting
  • Helios Klinikum Wuppertal GmbH
    Wuppertal, Germany
    Recruiting
    • Marco Speicher, MD · Contact
  • General Regional Hospital F. Miulli of Acquaviva delle Fonti
    Acquaviva delle Fonti, Bari, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Azienda Ospedaliero Universitaria di Parma
    Parma, PR 43126, Italy
    Not yet recruiting
  • Sant'Andrea Hospital - University of Rome "La Sapienza"
    Roma, RM 00189, Italy
    Active, not recruiting

    Not enrolling at this site.

  • San Giovanni Evangelista Hospital
    Tivoli, RM 00019, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
    Not yet recruiting
  • Fakultná nemocnica s poliklinikou Žilina
    Žilina, 01207, Slovakia
    Not yet recruiting
  • Stellenbosch University
    Cape Town, Western Cape 7505, South Africa
    Recruiting
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
    Recruiting
  • Hospital Universitario Parc Taulí
    Barcelona, 08208, Spain
    Recruiting
  • Hull University Teaching Hospitals NHS Trust
    Hull, United Kingdom
    Recruiting
    • Hermant Sharma, Prof. · Contact
  • Newcastle's Royal Victoria Infirmary
    Newcastle upon Tyne, NE14LP, United Kingdom
    Active, not recruiting

    Not enrolling at this site.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07079774
Lead sponsor
Orthofix s.r.l.
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Nov 24, 2025
Primary completion
Nov 24, 2028 (estimated)
Completion
Nov 24, 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

Jay Erturan, MD
Contact
jerturan@orthofix.co.uk
7779 32 32 44 ext. +44
Daniela Cangiano, PhD
Contact
danielacangiano@orthofix.it
0456719000 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion